A practical reference on CJC-1295: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-11 and is reviewed periodically as new material appears.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
== Modern herbal medicine == The World Health Organization (WHO) estimates that 80 percent of the population of some Asian and African countries presently uses herbal medicine for some aspect of primary health care. Some prescription drugs have a basis as herbal remedies, including artemisinin, digoxin, quinine and taxanes.
=== Welsh === Llanfairpwllgwyngyllgogerychwyrndrobwllllantysiliogogogoch, a railway station on the island of Anglesey in Wales, is the longest place name in the Welsh language. At 51 letters in the Welsh alphabet (the digraphs ll and ch are each collated as single letters) the name can be translated as "St Mary's church in the hollow of the white hazel near to the rapid whirlpool and the church of St Tysilio of the red cave". However, it was artificially contrived in the 1860s as a publicity stunt, to give the station the longest name of any railway station in the United Kingdom. Long words are comparatively rare in Welsh. Candidates for long words other than proper nouns include the following (the digraph dd is also treated as a single letter, as is ng in many instances including in the last word below):
In biology, organs are defined as confined functional units within an organism. The analogy of bodily organs to microscopic cellular substructures is obvious, as from even early works, authors of respective textbooks rarely elaborate on the distinction between the two. In the 1830s, Félix Dujardin refuted Ehrenberg's theory that microorganisms have the same organs as multicellular animals, only smaller. Credited as the first to use a diminutive of organ (i.e., little organ) for cellular structures was German zoologist Karl August Möbius (1884), who used the term organula (plural of organulum, the diminutive of Latin organum). In a footnote, which was published as a correction in the next issue of the journal, he justified his suggestion to call organs of unicellular organisms "organella" since they are only differently formed parts of one cell, in contrast to multicellular organs of multicellular organisms.
Sources: en.wikipedia.org
Anastomoses An anastomosis is a joining of two structures such as blood vessels. In the circulation these are called circulatory anastomoses, one of which is the join between an artery with a vein known as an arteriovenous anastomosis. This connection which is highly muscular, enables venous blood to travel directly from an artery into a vein without having passed from a capillary bed. Abnormal connections can be present known as arteriovenous malformations. These are usually congenital and the connections are made from a tangle of capillaries. A cerebral arteriovenous malformation is one that is located in the brain. An irregular connection between an artery and a vein is known as arteriovenous fistula. A small specialised arteriovenous anastomosis known as a glomus body or organ serves to transfer heat in the fingers and toes. The small connection is surrounded by a capsule of thickened connective tissue. In the hands and feet there are a great number of glomera.
== External links == Media related to Zearalenone at Wikimedia Commons Eriksen GS, Pennington J, Schlatter J (2000). "Zearalenone". WHO International Programme on Chemical Safety - Safety Evaluation of Certain Food Additives and Contaminants. Inchem. WHO Food Additives Series.
23 February A PAVN rocket attack on Da Nang Air Base destroyed a 450,000 gallon fuel tank beside the base and damaged a Marine A-6 Intruder. PAVN sappers attacked Hill 327 and the positions of the 2nd Battalion 7th Marines northwest of the Hill, both attacks were beaten back with 18 Marines killed and 80 wounded while the PAVN lost 75 killed or captured. A PAVN sapper attack on Dầu Tiếng Base Camp resulted in 21 U.S. and 73 PAVN killed. The PAVN 271st and 272nd Regiments attacked Patrol Base Diamond I occupied by the U.S. 2nd Battalion, 27th Infantry Regiment. The attack was repulsed with artillery and gunship fire with an estimated 118 PAVN killed and two captured.
IUPAC made a recommendation in 1991 for the description and measurement of carryover effects in clinical chemistry. The carryover ratio is the percentage of H3 carry to L1 constituting the carryover portion "h". In a design of 3 high samples followed by 3 low samples, h can be calculated as (L1 - mean of L2&L3) / (H3 - mean of L2&L3) The carry-over ratio's acceptance criteria depend on the measurement and the laboratory concerned. For example, 1% carryover of plasma albumin would generally lead to a clinically insignificant effect, while 1% carryover of cardiac High sensitivity Troponin assay would be catastrophic.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.